Form 4: Ocular Therapeutix CSO Sells Shares for Tax Obligations

Ocular Therapeutix's Chief Scientific Officer, Jeffrey S. Heier, sold 3,469 shares of common stock at a weighted average price of $12.04 to cover tax withholding obligations from restricted stock unit vesting.

Summary

• Jeffrey S. Heier, Chief Scientific Officer of Ocular Therapeutix, Inc. (OCUL), reported a sale of common stock.
• The transaction involved 3,469 shares of common stock.
• The shares were sold on November 24, 2025, at a weighted average price of $12.04 per share.
• The sale was executed pursuant to a durable automatic sale instruction adopted on April 9, 2024, under a Rule 10b5-1(c) plan.
• The purpose of the sale was to satisfy tax withholding obligations in connection with the vesting of restricted stock units (RSUs) on November 22, 2025.
• This sale does not represent a discretionary trade by the reporting person.
• Following the reported transaction, Jeffrey S. Heier beneficially owns 245,940 shares of common stock.
• The shares were sold in multiple transactions with prices ranging from $11.80 to $12.3207.

Sentiment

Score: 5

Explanation: The transaction is a routine, non-discretionary sale by an insider to cover tax obligations related to RSU vesting, executed under a pre-arranged 10b5-1 plan. It does not reflect a change in management's sentiment towards the company's prospects or any significant operational or financial event.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Management Comments

• The sales do not represent a discretionary trade by the reporting person.

Industry Context

This is a routine insider transaction, common for executives whose compensation includes restricted stock units. Such 'sell-to-cover' transactions are standard practice to manage tax liabilities upon RSU vesting and are typically executed under pre-arranged 10b5-1 plans to avoid accusations of insider trading.

Corporate Governance

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, non-discretionary sale for tax purposes, not indicative of a change in the insider's confidence in the company. The number of shares sold is a small fraction of the total outstanding shares.

Key Dates

Recommendation

The reported transaction is a standard 'sell-to-cover' for tax obligations related to RSU vesting, executed under a pre-established 10b5-1 plan. It is not a discretionary sale and therefore does not provide new information that would alter the fundamental investment thesis for Ocular Therapeutix. Investors should maintain their current position based on the company's operational performance and strategic outlook, rather than this routine insider filing.

Keywords

OCULAR THERAPEUTIX, OCUL, Form 4, Insider Transaction, Stock Sale, Jeffrey S. Heier, Chief Scientific Officer, RSU Vesting, Tax Withholding, 10b5-1 Plan